48 related articles for article (PubMed ID: 21247774)
1. Moderate Hyperkalemia Regulates Autophagy to Reduce Cerebral Ischemia-Reperfusion Injury in a CA/CPR Rat Model.
Wang X; Tian X; Shen H; Zhang X; Xie L; Chen M
Brain Sci; 2023 Sep; 13(9):. PubMed ID: 37759886
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Clinical Use of Levosimendan and Perspectives on its Future in Oncology.
Ribeiro E; Vale N
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759695
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan-induced venodilation is mediated by opening of potassium channels.
Burkhoff D; Rich S; Pollesello P; Papp Z
ESC Heart Fail; 2021 Dec; 8(6):4454-4464. PubMed ID: 34716759
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Comparisons among Inotropic Agents on Mortality and Risk of Renal Dysfunction in Patients Who Underwent Cardiac Surgery: A Network Meta-Analysis of Randomized Controlled Trials.
Chen WC; Lin MH; Chen CL; Chen YC; Chen CY; Lin YC; Hung CC
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33802296
[TBL] [Abstract][Full Text] [Related]
5. Use of levosimendan in acute and advanced heart failure: short review on available real-world data.
Pashkovetsky E; Gupta CA; Aronow WS
Ther Clin Risk Manag; 2019; 15():765-772. PubMed ID: 31354283
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan protects human hepatocytes from ischemia-reperfusion injury.
Brunner SN; Bogert NV; Schnitzbauer AA; Juengel E; Moritz A; Werner I; Kornberger A; Beiras-Fernandez A
PLoS One; 2017; 12(11):e0187839. PubMed ID: 29145424
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan Reduces Lung Injury in a Canine Model of Cardiopulmonary Bypass.
Feng J; Liu H; Chen J; Wang J; Liu Z; Ge S
Korean Circ J; 2016 May; 46(3):402-7. PubMed ID: 27275177
[TBL] [Abstract][Full Text] [Related]
8. The effect of levosimendan on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats.
Kiraz HA; Poyraz F; Kip G; Erdem Ö; Alkan M; Arslan M; Özer A; Şivgin V; Çomu FM
Libyan J Med; 2015 Jan; 10(1):29269. PubMed ID: 26649830
[TBL] [Abstract][Full Text] [Related]
9. Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.
Grossini E; Bellofatto K; Farruggio S; Sigaudo L; Marotta P; Raina G; De Giuli V; Mary D; Pollesello P; Minisini R; Pirisi M; Vacca G
PLoS One; 2015; 10(4):e0124742. PubMed ID: 25880552
[TBL] [Abstract][Full Text] [Related]
10. Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.
Nagy L; Pollesello P; Papp Z
J Cardiovasc Pharmacol; 2014 Sep; 64(3):199-208. PubMed ID: 24785346
[TBL] [Abstract][Full Text] [Related]
11. Acute and chronic cardioprotection by the enkephalin analogue, Eribis peptide 94, is mediated via activation of nitric oxide synthase and adenosine triphosphate-regulated potassium channels.
Gross GJ; Hsu A; Nithipatikom K; Pfeiffer AW; Bobrova I; Bissessar E
Pharmacology; 2012; 90(1-2):110-6. PubMed ID: 22814415
[TBL] [Abstract][Full Text] [Related]
12. Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts.
Matsumoto S; Cho S; Tosaka S; Higashijima U; Maekawa T; Hara T; Sumikawa K
Cardiovasc Diabetol; 2012 Jan; 11():4. PubMed ID: 22239823
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan cardioprotection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model.
Metzsch C; Liao Q; Steen S; Algotsson L
Acta Anaesthesiol Scand; 2007 Jan; 51(1):86-93. PubMed ID: 17073861
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan cardioprotection in acutely beta-1 adrenergic receptor blocked open chest pigs.
Metzsch C; Linnér R; Steen S; Liao Q; Algotsson L
Acta Anaesthesiol Scand; 2010 Jan; 54(1):103-10. PubMed ID: 19681782
[TBL] [Abstract][Full Text] [Related]
15. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition.
Hönisch A; Theuring N; Ebner B; Wagner C; Strasser RH; Weinbrenner C
Basic Res Cardiol; 2010 Mar; 105(2):155-67. PubMed ID: 19842009
[TBL] [Abstract][Full Text] [Related]
16. The cardioprotective effects of levosimendan: preclinical and clinical evidence.
Pollesello P; Papp Z
J Cardiovasc Pharmacol; 2007 Sep; 50(3):257-63. PubMed ID: 17878752
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
Mebazaa A; Erhardt L
Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
[TBL] [Abstract][Full Text] [Related]
18. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide.
Caimmi PP; Molinari C; Uberti F; Micalizzi E; Valente G; Mary DA; Vacca G; Grossini E
Eur J Cardiothorac Surg; 2011 Apr; 39(4):e59-67. PubMed ID: 21247774
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
